Effect of Rho-ROCK signaling pathway on pulmonary fibrosis

doi:10.5246/jcps.2016.01.001

Journal of Chinese Pharmaceutical Sciences ›› 2016, Vol. 25 ›› Issue (1): 3-11.DOI: 10.5246/jcps.2016.01.001

• Review • Previous Articles Next Articles

Effect of Rho-ROCK signaling pathway on pulmonary fibrosis

Wenying Yu¹, Chenhuan Yu¹, Wei Dai², Jieyin Sun^1*

1. Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China
2. Hangzhou Dongxiang Pharmaceutical Technology Co., Ltd., Hangzhou 310000, China

Received:2015-10-09 Revised:2015-11-04 Online:2016-01-27 Published:2015-11-10
Contact: Tel.: 0571-88215628, E-mail: sunjieyin@163.com
About author:Wenying Yu graduated from Zhejiang Chinese Medical University in 2008 and obtained her Master degree, majoring in pharmacy. After graduation, she was working in the Institute of Materia Medica, Zhejiang Academy of Medical Sciences. At present, she is in charge of Natural Science Foundation of Zhejiang Province, Administration of Traditional Chinese Medicine of Zhejiang Province and other research projects. As the technical backbone, she has developed at least 2 types of second grade national new medicine and obtained two national patents granted by China’s Patent Office. Her research interests include: (1) New drug targets discovery and targeted drug development; (2) Research and development of targeted drug delivery and controlled release drug delivery.
Supported by:
Zhejiang Provincial Natural Science Foundation of China (Grant No. LQ15H280007), National Natural Science Foundation of China (Grant No. 81202977), project of Traditional Chinese Medicine Science of Zhejiang province (Grant No. 2013ZA026 and 2016ZA042).

Abstract

Abstract:

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive lung scarring, reduced median survival, poor prognosis and limited therapeutic options, leading to great need for new pharmacologic therapies. In recent years, researchers have found that Rho-ROCK signaling pathway may be a new drug target in the prevention of IPF. This article reviewed the role of Rho-ROCK pathway in pulmonary fibrosis and the application of ROCK inhibitors in experimental models of IPF. Multiple lines of evidence therefore indicated that ROCK inhibition has great potential to be a powerful therapeutic tool in the prevention and treatment of IPF in clinic.

Key words: Rho-ROCK signaling pathway, Pulmonary fibrosis, Inhibitor, Drug targets

CLC Number:

R962.1

Supporting:

Wenying Yu, Chenhuan Yu, Wei Dai, Jieyin Sun. Effect of Rho-ROCK signaling pathway on pulmonary fibrosis[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(1): 3-11.

References

[1] Zhou, Y.; Huang, X.w.; Hecker, L.; Kurundkar, D.; Kurundkar, A.; Liu, H.; Jin, T.H.; Desai, L.; Bernard, K.; Thannickal, V. J. Clin. Invest. 2013, 123, 1096-1108.

[2] Zuo, Y.; Oh, W.; Frost, J.A. Cell Signal. 2014, 26, 2998-3006.

[3] Liao, J.K.; Seto, M.K. J. Cardiovasc. Pharmacol. 2007, 50, 17-24.

[4] Zhang, Y.M.; Bo, J.; Taffet, G.E.; Chang, J.; Shi, J.; Reddy, A.K.; Michael, L.H.; Schneider, M.D.; Entman, M.L.; Schwartz, R.J.; Wei, L. FASEB J. 2006, 20, 916-925.

[5] Fu, P.; Liu, F.; Su, S.; Wang, W.; Huang, X.R.; Entman, M.L.; Schwartz, R.J.; Wei, L.; Lan, H.Y. J. Am. Soc. Nephrol. 2006, 17, 3105-3114.

[6] Funke, M.; Zhao, Z.; Xu, Y.; Chun, J.; Tager, A.M. Am. J. Respir. Cell Mol. Biol. 2012, 46, 355-364.

[7] Wilhelm, K.R.; Roan, E.; Ghosh, M.C.; Parthasarathi, K.; Waters, C.M. FEBS J. 2014, 281, 957-969.

[8] Kono, Y.; Nishiuma, T.; Nishimura, Y.; Kotani, Y.; Okada, T.; Nakamura, S.; Yokoyama, M. Am. J. Respir. Cell Mol. Biol. 2007, 37, 395-404.

[9] Gauthaman, K.; Fong, C.Y.; Bongso, A. Stem Cell Rev. 2010, 6, 86-95.

[10] Horani, A.; Nath, A.; Wasserman, M.G.; Huang, T.; Brody, S.L. Am. J. Respir. Cell Mol. Biol. 2013, 49, 341-347.

[11] Lech, M.; Anders, H.J. Biochim. Biophys. Acta. 2013, 1832, 989-997.

[12] Washida, N.; Wakino, S.; Tonozuka, Y.; Homma, K.; Tokuyama, H.; Hara, Y.; Hasegawa, K.; Minakuchi, H.; Fujimura, K.; Hosoya, K.; Hayashi, K.; Itoh, H. Nephrol. Dial. Transplant. 2011, 26, 2770-2779.

[13] Wu, D.J.; Xu, J.Z.; Wu, Y.J.; Jean-Charles, L.; Xiao, B.; Gao, P.J.; Zhu, D.L. Atherosclerosis. 2009, 207, 68-73.

[14] Ishimaru, K.; Ueno, H.; Kagitani, S.; Takabayashi, D.; Takata, M.; Inoue, H. J. Cardiovasc. Pharmacol. 2007, 50, 187-194.

[15] Shimizu, Y.; Dobashi, K.; Iizuka, K.; Horie, T.; Suzuki, K.; Tukagoshi, H.; Nakazawa, T.; Nakazato, Y.; Mori, M. Am. J. Respir. Crit. Care Med. 2001, 163, 210-217.

[16] Wang, H.W.; Liu, P.Y.; Oyama, N.; Rikitake, Y.; Kitamoto, S.; Gitlin, J.; Liao, J.K.; Boisvert, W.A. FASEB J. 2008, 22, 3561-3570.

[17] Raghu, G.; Anstrom, K.J.; King, T.E. J.r.; Lasky, J.A.; Martinez, F.J. N. Engl. J. Med. 2012, 366, 1968-1977.

[18] Wojciak-Stothard, B.; Ridley, A.J. Vascul. Pharmacol. 2002, 39, 187-199.

[19] Sun, H.; Breslin, J.W.; Zhu, J.; Yuan, S.Y.; Wu, M.H. Microcirculation. 2006, 13, 237-247.

[20] Takemoto, M.; Sun, J.; Hiroki, J.; Shimokawa, H.; Liao, J.K. Circulation. 2002, 106, 57-62.

[21] Park, I.H.; Park, S.J.; Cho, J.S.; Moon, Y.M.; Moon, J.H.; Kim, T.H.; Lee, S.H.; Lee, H.M. Am. J. Rhinol. Allergy. 2012, 26, 7-11.

[22] Sisson, T.H.; Ajayi, I.O.; Subbotina, N.; Dodi, A.E.; Rodansky, E.S.; Chibucos, L.N.; Kim, K.K.; Keshamouni, V.G.; White, E.S.; Zhou, Y.; Higgins, P.D.; Larsen, S.D.; Neubig, R.R.; Horowitz, J.C. Am. J. Pathol. 2015, 185, 969-986.

[23] Mueller, B.K.; Mack, H.; Teusch, N. Nat. Rev. Drug Discov. 2005, 4, 387-398.

[24] Justus, C.R.; Yang, L.V. Exp. Cell Res. 2015, 334, 100-113.

[25] Wang, H.L.; Hu, S.H.; Chou, A.H.; Wang, S.S.; Weng, Y.H.; Yeh, T.H. Neuropharmacology. 2013, 70, 1-11.

[26] Wang, X.K.; Wang, Y.G.; Chai, Y.H.; Hu, J.; Zhan, H.L.; Xing, D.M.; You, X.F.; Wang, Z.M.; Yang, X.W.; Lei, F.; Du, L.J. J. Chin. Pharm. Sci. 2012, 21, 436-447.

[27] Okumura, N.; Nakano, S.; Kay, E.P.; Numata, R.; Ota, A.; Sowa, Y.; Sakai, T.; Ueno, M.; Kinoshita, S.; Koizumi, N. Invest. Ophthalmol. Vis. Sci. 2014, 55, 318-329.

[28] Patel, R.A.; Forinash, K.D.; Pireddu, R.; Sun, Y.; Sun, N.; Martin, M.P.; Schonbrunn, E.; Lawrence, N.J.; Sebti, S.M. Cancer Res. 2012, 72, 5025-5034.

[29] Akahori, H.; Tsujino, T.; Naito, Y.; Matsumoto, M.; Sasaki, N.; Iwasaku, T.; Eguchi, A.; Sawada, H.; Hirotani, S.; Masuyama, T. J. Hypertens. 2014, 32, 1534-1541.

[30] Forgione, N.; Fehlings, M.G. World Neurosurg. 2014, e535-539.

[31] Isler, D.; Ozaslan, M.; Karagoz, I.D.; Kilic, I.H.; Karakok, M.; Taysi, S.; Guler, I.; Cakmak, A.; Demiryurek, A.T. Pharmacol. Rep. 2014, 66, 114-120.

[32] Matoba, K.; Kawanami, D.; Okada, R.; Tsukamoto, M.; Kinoshita, J.; Ito, T.; Ishizawa, S.; Kanazawa, Y.; Yokota, T.; Murai, N.; Matsufuji, S.; Takahashi-Fujigasaki, J.; Utsunomiya, K. Kidney Int. 2013, 84, 545-554.

[33] Xiao, J.W.; Zhu, X.Y.; Wang, Q.G.; Zhang, D.Z.; Cui, C.S.; Zhang, P.; Chen, H.Y.; Meng, L.L. Circ. J. 2015, 79, 1342-1348.

[34] Zhou, H.; Fang, C.; Zhang, L.; Deng, Y.; Wang, M.; Meng, F. Chin. Med. J. (Engl.) 2014, 127, 225-231.

[35] Qi, X.J.; Li, J.; Xu, F.; Fang, F. J. Shanghai Jiaotong University. 2014, 34, 1442-1447.

[36] Ni, J.; Dong, Z.; Han, W.; Kondrikov, D.; Su, Y. Free Radic. Biol. Med. 2013, 61, 26-39.

[37] Jiang, C.; Huang, H.; Liu, J.; Wang, Y.; Lu, Z.; Xu, Z. Int. J. Mol. Sci. 2012, 13, 8293-8307.

[38] Chen, Y.Y.;Zhou, Y.; Tan, M.Q. Shanxi Med. J. 2015, 7-11.

[39] Kim, J.W.; Rhee, C.K.; Kim, T.J.; Kim, Y.H.; Lee, S.H.; Yoon, H.K.; Kim, S.C.; Lee, S.Y.; Kwon, S.S.; Kim, K.H.; Kim, Y.K. Clin. Exp. Pharmacol. Physiol. 2010, 37, 1055-1063.

[40] Huang, L. Master. thesis, Zhengzhou University. 2013.

[41] Monceau, V.; Pasinetti, N.; Schupp, C.; Pouzoulet, F.; Opolon, P.; Vozenin, M.C. Curr. Drug Targets. 2010, 11, 1395-1404.

[42] Bagnato, G.; Bitto, A.; Pizzino, G.; Irrera, N.; Sangari, D.; Cinquegrani, M.; Roberts, W.N.; Matucci, Cerinic, M.; Squadrito, F.; Altavilla, D.; Bagnato, G.; Saitta, A. Rheumatology. 2013, 52, 1377-1386.

[43] Li, S.Y.; Xu, H.; Sun, Y.; Yuan, Y.; Deng, H.J.; Ma, W.D.; Wei, Z.Q.; Yang, Y.; Wang, R.M.; Yang, F. Chin. Occup. Med. 2013, 40, 95-99.

[44] Jolly, L.; Stavrou, A.; Vanderstoken, G.; Meliopoulos, V.A.; Habgood, A.; Tatler, A.L.; Porte, J.; Knox, A.; Weinreb, P.; Violette, S.; Hussell, T.; Kolb, M.; Stampfli, M.R.; Schultz-Cherry, S.; Jenkins, G. J. Biol. Chem. 2014, 289, 35246-35263.

Effect of Rho-ROCK signaling pathway on pulmonary fibrosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xiaowei Chi, Qi Li, Yi Zhong, Tong Gong, Chuxiao Yi, Liangren Zhang, Zhenming Liu. Discovery of potential xanthine oxidase inhibitors based on virtual screening [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 626-635.
[2]	Yuxia Zhu, Lingjian Zhang, Yiming Hu, Weihua Liu, Liping Guan, Lin Lin. Study on synthesis of naringenin derivatives and cholinesterase inhibitory activity in marine Chinese medicine [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 636-644.
[3]	Chonghao Wu, Panjie Huang, Chunqi Yang, Chuan Gao, Ming Zeng. The efficacy and safety of immune checkpoint inhibitors in malignant pleural mesothelioma: A systematic review [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 291-301.
[4]	Xiaohui Li, Qian Wang, Chennan Liu, Jiangxue Han, Sihan Liu, Tianjun Liu, Qian Wang, Yan Guan, Chunling Xiao, Xiao Wang, Yishuang Liu. PHT427 functions as a novel inhibitor of KPC-2 [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(12): 989-997.
[5]	Ying Fu, Simo Liu, Yan Ma, Nannan Wu. Canagliflozin, an inhibitor of sodium-glucose co-transporter 2, advances in the treatment of type 2 diabetes [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(8): 569-588.
[6]	Qian Wang, Chennan Liu, Jiangxue Han, Sihan Liu, Chunling Xiao, Yan Guan, Xinghua Li, Ying Wang, Xiao Wang, Jianzhou Meng, Maoluo Gan, Yishuang Liu. (–)-Epicatechin gallate serves as a novel new delhi metallo-β-lactamase-1 (NDM-1) inhibitor [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 716-724.
[7]	Aris Stiawan, Eti Nurwening Sholikhah, Yehezkiel Steven Kurniawan, Yoga Priastomo, Jumina. Synthesis, cytotoxicity assay, and molecular docking study of hydroxychalcone derivatives as potential tyrosinase inhibitors [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(8): 634-644.
[8]	Chunxing Li, Yuanmin Zhu, Hua Liu, Zhao Xu. Efficacy of prokinetic drugs in combination with proton pump inhibitors versus proton pump inhibitors alone in the treatment of gastroesophageal reflux disease: a meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 347-356.
[9]	Shaohong Luo, Liangliang Dong, Yiyuan Li, Dan Xu, Min Chen. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 253-263.
[10]	Jing Zhou, Hong Zhang, Xiaojiao Li, Xiangshi Song, Mengmeng Zhang, Yanhua Ding. Analysis of the effect of HCV resistance-associated substitutions on the short-term efficacy of DAA after single administration in three phase Ib clinical trials [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(2): 133-145.
[11]	Yan Zhou, Hengwen Song, Zhichao Shao, Bomin Yin, Ximei Fu, Dianyou Xie, Lijun Wei. Preclinical efficacy of a novel cyclin-dependent kinase 9 inhibitor, QHRD107 against acute myeloid leukemia [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(2): 146-156.
[12]	State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The group of Professor Xiaoda Yang has made important progress in protein phosphatase inhibitors based on vanadium active groups [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(11): 932-933.
[13]	Chennan Liu, Qian Wang, Jiangxue Han, Sihan Liu, Chunling Xiao, Yan Guan, Xinghua Li, Ying Wang, Xiao Wang, Jianzhou Meng, Maoluo Gan, Yishuang Liu. Virtual screening and high-throughput testing of L1 metallo-β-lactamase inhibitor [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(10): 806-812.
[14]	State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The group of Professor Xinjing Tang has made progress in the study of cyclic antisense oligonucleotides as microRNA inhibitors [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(10): 855-856.
[15]	Ying Kang, Chanjuan Zhang, He Zhang, Dong Liu. Secondary metabolites from a deep-sea-derived Aspergillus versicolor F77 [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(1): 42-48.